Organoids Rebuild Autoimmune Disease Tissue by Tissue, Opening a Path to Personalized Immunology

Autoimmune diseases have long been framed as failures of immune tolerance, but a growing body of evidence suggests that the real story unfolds in the tissue itself. A new review published in Bioengineering & Translational Medicine argues that conditions such as systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis are driven by progressive reprogramming of local tissue microenvironments—changes in extracellular matrix mechanics, stromal and endothelial plasticity, interferon amplification loops, metabolic stress, and barrier dysfunction. The authors, led by researchers at the Catholic University of Korea, contend that conventional cell cultures and animal models capture only fragments of these complex human states, and they lay out a roadmap for rebuilding autoimmune pathology inside engineered organoids and organ-on-a-chip systems.

The central insight of the review is that autoimmune pathology emerges within spatially organized inflammatory niches rather than from isolated molecular defects. In systemic sclerosis, early microvascular destabilization driven by oxidative stress and anti-endothelial autoantibodies triggers endothelial apoptosis and endothelial-to-mesenchymal transition. Fibroblasts then undergo metabolic and epigenetic reprogramming, marked by persistent activation of the mechanotransductive regulators YAP/TAZ and MRTF-A, which keeps collagen production running even after soluble inflammatory cues fade. This creates what the authors call mechanical memory: extracellular matrix accumulates, tissue stiffens, and the stiffening itself amplifies fibroblast activation in a self-reinforcing loop that consolidates fibrosis in skin and lung.

Systemic lupus erythematosus follows a different but equally structured trajectory. Nucleic acid-containing immune complexes deposit along vascular and epithelial interfaces, where they activate plasmacytoid dendritic cells, neutrophils, and stromal cells through Fcγ receptors and the innate nucleic acid sensors TLR7 and TLR9. The result is robust type I interferon production, which conditions epithelial and endothelial layers to become fragile, reducing their mitochondrial reserve and increasing sensitivity to complement attack and mechanical stress. Spatial transcriptomics of patient tissue reveals persistent interferon hubs where interferon-stimulated genes remain highly expressed and tight junction maintenance is impaired. NET-associated oxidized mitochondrial DNA further activates the cGAS–STING pathway, intensifying interferon signaling and vascular dysfunction in a feed-forward cascade.

Rheumatoid arthritis, meanwhile, centers on cytokine-saturated stromal invasion. Autoantibodies against citrullinated antigens activate macrophages and neutrophils, flooding the synovium with TNF, IL-1β, IL-6, and GM-CSF. Within this niche, fibroblast-like synoviocytes rewire their metabolism toward glycolysis, activate AP-1/NF-κB enhancer programs, and resist apoptosis, differentiating into invasive subsets. Lining-layer synoviocytes secrete MMP and ADAMTS proteases that degrade cartilage, while sublining populations recruit immune cells through CXCL12 and GM-CSF. The stromal programs also drive RANKL-dependent osteoclastogenesis, linking inflammation directly to bone destruction. Each disease, in other words, selectively amplifies shared microenvironmental circuits—matrix remodeling, barrier destabilization, and self-sustaining cytokine loops—into a distinct pathogenic axis.

The review’s key contribution is translating these axes into engineering specifications. For systemic sclerosis, models must incorporate dynamically stiffening matrices, endothelial compartments capable of undergoing endothelial-to-mesenchymal transition under shear stress, and oxygen- and pressure-responsive microenvironments. Photoresponsive or enzyme-remodeled hydrogels allow researchers to interrogate mechanical memory acquisition directly, while perfusable microvascular chips reproduce shear-dependent endothelial activation under controlled oxygen tension and reactive oxygen species exposure. Existing iPSC-derived skin organoids exposed to TGF-β, IL-6, or patient serum already reproduce collagen accumulation, α-SMA induction, and SMAD and ERK signaling, preserving donor-specific fibroblast epigenetic states that reflect individual profibrotic sensitivity.

For lupus, the engineering requirements center on flow-dependent immune-complex deposition and interferon-responsive barrier tissues. Intestinal organoids exposed to lupus serum exhibit robust type I interferon activation, tight-junction disruption, reduced goblet-cell differentiation, and falling transepithelial electrical resistance. Kidney organoids and glomerular chips model immune-complex deposition, complement-mediated podocyte injury, and endothelial activation, while cardiac spheroids exposed to anti-Ro autoantibodies reproduce fibrosis, hypertrophy, and disrupted calcium signaling. Because lupus behaves as a multi-organ interferonopathy, the authors argue that multicompartment perfusion platforms are needed to recreate interferon gradients, cytokine spillover, and immune-complex trafficking across gut, kidney, heart, and vascular interfaces—something no single-organ model can achieve.

Rheumatoid arthritis platforms take a different form. Synovial organoids composed of patient-derived fibroblast-like synoviocytes, macrophages, and endothelial cells self-organize into persistent TNF/IL-6/GM-CSF niches that stabilize invasive stromal phenotypes and pathological angiogenesis—features absent from two-dimensional cultures. Joint-on-a-chip systems go further, spatially coupling synovium-like tissue with cartilage and bone matrices under flow and cyclic mechanical loading, enabling real-time observation of protease-mediated cartilage erosion and osteoclast-driven bone resorption as integrated mechanisms of joint destruction. Multicellular spheroids stimulated with synovial fluid or VEGF produce pannus-like outgrowth and macrophage-dependent inflammatory amplification, extending the framework toward drug screening.

Personalization is where the platform concept becomes clinically ambitious. Patient-derived induced pluripotent stem cells retain donor-specific transcriptional and epigenetic features, including genetic risk variants. CRISPR editing allows direct interrogation of disease genes: introducing lupus-risk variants such as DNASE1L3, IRF5, STAT4, and TLR7 enhances interferon responsiveness, while correcting pathogenic alleles restores barrier integrity. Editing HLA-DRB1 shared-epitope sequences or PTPN22 variants in rheumatoid arthritis organoids modulates T-cell help and Th17 polarization. A third layer comes from serum-based personalization, in which exposure to patient sera enriched for specific autoantibodies—ACPA, anti-Ro, anti-RNP, or anti-PDGFR—produces donor-specific fibrosis, interferon activation, or matrix degradation. Iteratively tuning organoid conditions until transcriptomic and structural profiles converge with biopsy signatures could yield what the authors call organoid digital twins capable of patient-specific therapeutic testing.

The engineering toolkit underpinning these models is itself a major theme. Synthetic PEG-based hydrogels with tunable crosslinking kinetics allow stiffness to be matched quantitatively to diseased tissue ranges, from sub-kilopascal basement-membrane-like matrices for lupus barrier fragility to tens-of-kilopascal collagen networks for scleroderma dermis. Viscoelastic properties such as stress relaxation shape integrin clustering, cytoskeletal tension, and nuclear deformation, while protease-cleavable linkers permit real-time quantification of matrix degradation. Spatial patterning techniques—micropatterned co-cultures, photo-patterned hydrogels, chemokine-laden matrices—position immune cells relative to stromal compartments, recreating perivascular interferon hubs, fibrotic immune aggregates, and invasive pannus fronts. Analytical tools including atomic force microscopy, second-harmonic generation imaging, single-cell RNA sequencing, spatial transcriptomics, and matrisome proteomics convert fibrosis, barrier failure, and immune infiltration into measurable engineering parameters.

The authors are candid about the limitations. iPSC-derived cells often retain fetal-like metabolic and epigenetic states, limiting their ability to adopt adult activation thresholds. Most organoid cultures cannot sustain matrix architecture, immune organization, or barrier integrity long enough to model slow fibrosis progression or flare–remission cycles, and disease-relevant dynamics such as oscillatory interferon activity rarely emerge spontaneously in vitro. Autoantibody repertoires, which arise from affinity maturation and epitope spreading within germinal center-like ecosystems, are mostly approximated by bulk patient serum. Multi-organ integration, systemic immune circulation, neuroendocrine regulation, reproducibility standards, cost, and throughput all remain unresolved. Yet the trajectory is clear: as biomaterials engineering, stem cell biology, immunology, and computational modeling converge, autoimmune organoids may evolve from descriptive reconstructions into predictive, patient-calibrated microphysiological ecosystems—supporting antifibrotic drug screening for systemic sclerosis, interferon- and complement-targeted strategies for lupus, and combination therapy optimization for rheumatoid arthritis, potentially reducing reliance on animal models along the way.

Subject of Research: Engineering organoid and organ-on-a-chip models of autoimmune diseases for precision medicine

Article Title: Engineering autoimmune disease models using organoids: Harnessing microenvironmental engineering for precision medicine and immunological recapitulation

Article References: Lee, C.-J., Kim, Y., Kim, M., Rim, Y. A., & Ju, J. H. (2026). Engineering autoimmune disease models using organoids: Harnessing microenvironmental engineering for precision medicine and immunological recapitulation. Bioengineering & Translational Medicine, Article e70162. https://doi.org/10.1002/btm2.70162

Image Credits: AI Generated

DOI: 10.1002/btm2.70162

Keywords: organoids, autoimmune disease, systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis, organ-on-a-chip, microenvironment, iPSC, interferon signaling, fibrosis, precision medicine, extracellular matrix